VF
FDMT icon

Virtu Financial’s 4D Molecular Therapeutics FDMT Stock Holding History

Virtu Financial’s Portfolio FDMT Stock Details FDMT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$245K Buy
+26,368
New +$229K 0.01% 919
2025
Q3 		– Sell
-12,648
Closed -$47K – 1662
2025
Q2 		$47K Buy
+12,648
New +$44.5K ﹤0.01% 1148

Other funds holding FDMT

Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Virtu Financial's FDMT Position: Q1 2026 in Review

Virtu Financial opened a new position in 4D Molecular Therapeutics (FDMT) in Q1 2026: 26,368 shares worth $245K. The stake represents 0.01% of the portfolio and ranks #919 among its holdings. This is a return to the name: Virtu Financial previously reported a position in FDMT as recently as Q2 2025.

Virtu Financial first reported a position in FDMT in Q2 2025 and has held it in 2 quarters since. 152 funds tracked by Wall St. Rank hold FDMT as of Q1 2026.

  • Virtu Financial held 26,368 shares of 4D Molecular Therapeutics worth $245K as of Q1 2026.
  • 4D Molecular Therapeutics was a new Virtu Financial position in Q1 2026.
  • 4D Molecular Therapeutics made up 0.01% of Virtu Financial's portfolio in Q1 2026, its #919 holding.
  • Virtu Financial first reported a position in 4D Molecular Therapeutics in Q2 2025 and has held it in 2 quarters since.
  • 152 funds tracked by Wall St. Rank held 4D Molecular Therapeutics as of Q1 2026.

Based on Virtu Financial's 13F filing for Q1 2026, filed 14 May 2026.